Molecular	O
regulation	O
of	O
human	B-protein
interleukin	I-protein
2	I-protein
and	O
T-cell	B-cell_type
function	O
by	O
interleukin	B-protein
4	I-protein
.	O

Distinct	O
functional	O
T-cell	B-cell_type
subsets	I-cell_type
,	O
differing	O
in	O
the	O
patterns	O
of	O
lymphokines	B-protein
produced	O
,	O
regulate	O
cell-mediated	O
and	O
humoral	O
immune	O
responses	O
.	O

The	O
two	O
major	O
types	O
and	O
their	O
principal	O
products	O
,	O
interleukin	B-protein
4	I-protein
and	O
interferon	B-protein
gamma	I-protein
(	O
IL-4	B-protein
and	O
IFN-gamma	B-protein
)	O
,	O
are	O
reciprocally	O
negatively	O
interactive	O
.	O

To	O
analyze	O
the	O
molecular	O
mechanism	O
of	O
IL-4-mediated	O
suppression	O
of	O
cell-mediated	O
immunity	O
we	O
studied	O
its	O
effects	O
on	O
expression	O
of	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
and	O
IFN-gamma	B-protein
.	O

IL-4	B-protein
pretreatment	O
of	O
Jurkat	B-cell_type
cells	I-cell_type
prior	O
to	O
stimulation	O
resulted	O
in	O
a	O
decrease	O
in	O
transcription	O
of	O
the	O
IL2	B-DNA
gene	I-DNA
.	O

IL-4	B-protein
suppressed	O
IL-2	O
and	O
IFN-gamma	O
mRNA	O
levels	O
in	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
and	O
addition	O
of	O
anti-CD28	B-protein
antibodies	I-protein
relieved	O
this	O
suppression	O
.	O

Using	O
enhancer-reporter	B-DNA
constructs	I-DNA
,	O
IL-4	B-protein
specifically	O
down-regulated	O
the	O
NFIL-2B	B-DNA
element	I-DNA
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
using	O
a	O
DNA	O
oligomer	O
containing	O
the	O
NFIL-2B	B-DNA
binding	I-DNA
site	I-DNA
indicated	O
that	O
IL-4	B-protein
inhibited	O
the	O
NFIL-2B	B-protein
complex	I-protein
and	O
that	O
the	O
NFIL-2B	B-protein
DNA	I-protein
binding	I-protein
factor	I-protein
is	O
distinct	O
from	O
AP-	B-protein
1	O
.	O

These	O
results	O
suggest	O
that	O
IL-4	B-protein
may	O
regulate	O
development	O
and	O
function	O
of	O
T-cell	B-cell_type
subsets	I-cell_type
involved	O
in	O
cell-mediated	O
immunity	O
in	O
part	O
by	O
inhibiting	B-protein
factors	I-protein
required	O
for	O
transcription	O
of	O
the	O
IL2	B-DNA
gene	I-DNA

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

90	NULL
,	NULL
pp	NULL
.	NULL

7734-7738	NULL
,	NULL
August	NULL
1993	NULL
Immunology	NULL
Molecular	NULL
regulation	NULL
of	NULL
human	NULL
interleukin	NULL
2	NULL
and	NULL
T-cell	NULL
function	NULL
by	NULL
interleukin	NULL
4	NULL
EpwaArDp	NULL
M.	NULL
SCHWARZ	NULL
,	NULL
PaADMINI	NULL
SALGAME	NULL
,	NULL
AnD	NULL
BARRY	NULL
R.	NULL
BLOOM	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
,	NULL
Albert	NULL
Einstein	NULL
College	NULL
of	NULL
Medicine	NULL
,	NULL
Bronx	NULL
,	NULL
NY	NULL
10461	NULL
Contributed	NULL
by	NULL
Barry	NULL
R.	NULL
Bloom	NULL
,	NULL
May	NULL
18	NULL
,	NULL
1993	NULL
ABSTRACT	NULL
_	NULL
Distinct	NULL
functional	NULL
T-cell	NULL
subsets	NULL
,	NULL
differing	NULL
in	NULL
the	NULL
patterns	NULL
of	NULL
lymphokines	NULL
produced	NULL
,	NULL
regulate	NULL
cell-mediated	NULL
and	NULL
humoral	NULL
immune	NULL
responses	NULL
.	NULL

The	NULL
two	NULL
major	NULL
types	NULL
and	NULL
their	NULL
principal	NULL
products	NULL
,	NULL
interleukin	NULL
4	NULL
and	NULL
interferon	NULL
y	NULL
(	NULL
IL-4	NULL
and	NULL
IFN-y	NULL
)	NULL
,	NULL
are	NULL
reciprocally	NULL
negatively	NULL
interactive	NULL
.	NULL

To	NULL
analyze	NULL
the	NULL
molecular	NULL
mechanism	NULL
of	NULL
IL-4-mediated	NULL
suppression	NULL
of	NULL
cell-mediated	NULL
immunity	NULL
we	NULL
studied	NULL
its	NULL
effects	NULL
on	NULL
expression	NULL
of	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
and	NULL
IFN-y	NULL
.	NULL

IL-4	NULL
pretreatment	NULL
of	NULL
Jurkat	NULL
cells	NULL
prior	NULL
to	NULL
stimulation	NULL
resulted	NULL
in	NULL
a	NULL
decrease	NULL
in	NULL
transcription	NULL
of	NULL
the	NULL
IL2	NULL
gene	NULL
.	NULL

IL-4	NULL
suppressed	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
mRNA	NULL
levels	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
addition	NULL
of	NULL
anti-CD28	NULL
antibodies	NULL
relieved	NULL
this	NULL
suppression	NULL
.	NULL

Using	NULL
enhancer-reporter	NULL
constructs	NULL
,	NULL
IL-4	NULL
specifically	NULL
down-regulated	NULL
the	NULL
NFIL-2B	NULL
element	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
using	NULL
a	NULL
DNA	NULL
oligomer	NULL
containing	NULL
the	NULL
NFIL-2B	NULL
binding	NULL
site	NULL
indicated	NULL
that	NULL
IL-4	NULL
inhibited	NULL
the	NULL
NFIL-2B	NULL
complex	NULL
and	NULL
that	NULL
the	NULL
NFIL-2B	NULL
DNA	NULL
binding	NULL
factor	NULL
is	NULL
distinct	NULL
from	NULL
AP-1	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
IL-4	NULL
may	NULL
regulate	NULL
development	NULL
and	NULL
function	NULL
of	NULL
T-cell	NULL
subsets	NULL
involved	NULL
in	NULL
cell-mediated	NULL
immunity	NULL
in	NULL
part	NULL
by	NULL
inhibiting	NULL
factors	NULL
required	NULL
for	NULL
transcription	NULL
of	NULL
the	NULL
ZL2	NULL
gene	NULL
.	NULL

Functional	NULL
T-cell	NULL
subsets	NULL
have	NULL
been	NULL
defined	NULL
in	NULL
human	NULL
and	NULL
mouse	NULL
cells	NULL
by	NULL
their	NULL
surface	NULL
markers	NULL
and	NULL
the	NULL
patterns	NULL
of	NULL
lymphokines	NULL
produced	NULL
.	NULL

Type	NULL
1	NULL
CD4	NULL
(	NULL
Th1	NULL
)	NULL
and	NULL
CD8	NULL
(	NULL
cyto-toxic	NULL
T	NULL
lymphocyte	NULL
)	NULL
T	NULL
cells	NULL
producing	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
and	NULL
interferon	NULL
y	NULL
(	NULL
IFN-y	NULL
)	NULL
serve	NULL
as	NULL
effector	NULL
cells	NULL
for	NULL
cell-mediated	NULL
immunity	NULL
,	NULL
whereas	NULL
type	NULL
2	NULL
CD4	NULL
(	NULL
Th2	NULL
)	NULL
cells	NULL
that	NULL
regulate	NULL
antibody	NULL
formation	NULL
and	NULL
type	NULL
2	NULL
CD8	NULL
T	NULL
cells	NULL
that	NULL
have	NULL
suppressor	NULL
activity	NULL
produce	NULL
interleukin	NULL
4	NULL
(	NULL
IL-4	NULL
)	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

IL-4	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
exert	NULL
immunosuppressive	NULL
effects	NULL
on	NULL
cell-mediated	NULL
immunity	NULL
and	NULL
resistance	NULL
to	NULL
Leishmania	NULL
and	NULL
Schistosome	NULL
parasites	NULL
in	NULL
murine	NULL
systems	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

CD8	NULL
T	NULL
cells	NULL
with	NULL
mRNA	NULL
for	NULL
IL-4	NULL
predominate	NULL
in	NULL
lesions	NULL
of	NULL
antigen-unresponsive	NULL
patients	NULL
with	NULL
lepromatous	NULL
leprosy	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Clones	NULL
of	NULL
such	NULL
T	NULL
cells	NULL
suppress	NULL
in	NULL
vitro	NULL
responses	NULL
of	NULL
antigen-responsive	NULL
CD4	NULL
cells	NULL
,	NULL
and	NULL
production	NULL
of	NULL
IL-4	NULL
appears	NULL
to	NULL
be	NULL
a	NULL
necessary	NULL
condition	NULL
for	NULL
in	NULL
vitro	NULL
suppression	NULL
by	NULL
many	NULL
(	NULL
3	NULL
)	NULL
if	NULL
not	NULL
all	NULL
(	NULL
39	NULL
)	NULL
.	NULL

The	NULL
present	NULL
work	NULL
explores	NULL
the	NULL
hypothesis	NULL
that	NULL
the	NULL
suppressive	NULL
effects	NULL
of	NULL
IL-4	NULL
result	NULL
from	NULL
transcriptional	NULL
down-regulation	NULL
of	NULL
lymphokine	NULL
genes	NULL
functionally	NULL
required	NULL
by	NULL
type	NULL
1	NULL
T	NULL
cells	NULL
to	NULL
generate	NULL
cell-mediated	NULL
responses	NULL
,	NULL
particularly	NULL
L2	NULL
and	NULL
IFNG	NULL
(	NULL
IFN-y	NULL
gene	NULL
)	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
Culture	NULL
,	NULL
Lymphokines	NULL
,	NULL
and	NULL
Antibodies	NULL
.	NULL

lacZ	NULL
Jurkat	NULL
lines	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
L.	NULL
A.	NULL
Herzenberg	NULL
(	NULL
Stanford	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
grown	NULL
as	NULL
described	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Recombinant	NULL
human	NULL
IL-4	NULL
(	NULL
specific	NULL
activity	NULL
,	NULL
10	NULL
``	NULL
units/mg	NULL
)	NULL
was	NULL
generously	NULL
provided	NULL
by	NULL
P.	NULL
Trotta	NULL
(	NULL
Schering	NULL
,	NULL
Bloomfield	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
Sigma	NULL
.	NULL

Ionomycin	NULL
was	NULL
obtained	NULL
from	NULL
Calbiochem	NULL
.	NULL

The	NULL
monoclonal	NULL
antibody	NULL
(	NULL
mAb	NULL
)	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

7734	NULL
9.3	NULL
was	NULL
obtained	NULL
from	NULL
Oncogen	NULL
and	NULL
the	NULL
mAb	NULL
OKT3	NULL
was	NULL
provided	NULL
by	NULL
A.	NULL
D.	NULL
Donnenberg	NULL
(	NULL
Seattle	NULL
,	NULL
WA	NULL
)	NULL
.	NULL

Exponentially	NULL
growing	NULL
Jurkat	NULL
,	NULL
Raji	NULL
,	NULL
and	NULL
U937	NULL
cells	NULL
were	NULL
seeded	NULL
at	NULL
3	NULL
x	NULL
10°	NULL
per	NULL
ml	NULL
with	NULL
or	NULL
without	NULL
IL-4	NULL
(	NULL
500	NULL
units/ml	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
for	NULL
24	NULL
hr	NULL
and	NULL
then	NULL
stimulated	NULL
for	NULL
5	NULL
hr	NULL
with	NULL
20	NULL
ng	NULL
of	NULL
PMA	NULL
per	NULL
ml	NULL
and	NULL
2	NULL
uM	NULL
ionomycin	NULL
.	NULL

The	NULL
CD28	NULL
stimulated	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
1:500	NULL
dilution	NULL
of	NULL
mAb	NULL
9.3	NULL
ascites	NULL
for	NULL
5	NULL
hr	NULL
.	NULL

Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBLs	NULL
)	NULL
(	NULL
2	NULL
x	NULL
10	NULL
``	NULL
per	NULL
ml	NULL
)	NULL
were	NULL
activated	NULL
with	NULL
a	NULL
1:400	NULL
dilution	NULL
of	NULL
anti-CD3	NULL
OKT	NULL
3	NULL
ascites	NULL
added	NULL
to	NULL
the	NULL
CD28	NULL
stimulated	NULL
cells	NULL
for	NULL
5	NULL
hr	NULL
.	NULL

Northern	NULL
Analysis	NULL
.	NULL

RNA	NULL
was	NULL
isolated	NULL
by	NULL
guanidium	NULL
thio-cyanate	NULL
from	NULL
10	NULL
``	NULL
cells	NULL
and	NULL
Northern	NULL
blots	NULL
were	NULL
carried	NULL
out	NULL
using	NULL
the	NULL
glyoxal	NULL
method	NULL
(	NULL
8	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
probes	NULL
were	NULL
made	NULL
by	NULL
random	NULL
priming	NULL
cDNA	NULL
inserts	NULL
(	NULL
1.2-kb	NULL
IL-2	NULL
cDNA	NULL
,	NULL
0.5-kb	NULL
IFN-y	NULL
cDNA	NULL
,	NULL
and	NULL
2.0-kb	NULL
yactin	NULL
cDNA	NULL
)	NULL
.	NULL

Blots	NULL
were	NULL
subjected	NULL
to	NULL
autoradiography	NULL
and	NULL
hybridization	NULL
intensity	NULL
of	NULL
the	NULL
gene-specific	NULL
probes	NULL
was	NULL
measured	NULL
using	NULL
the	NULL
Computing	NULL
Densitometer	NULL
TM	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
)	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
cellular	NULL
RNA	NULL
was	NULL
isolated	NULL
at	NULL
indicated	NULL
times	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
actinomycin	NULL
D	NULL
(	NULL
10	NULL
mg/ml	NULL
)	NULL
and	NULL
analyzed	NULL
by	NULL
Northern	NULL
analysis	NULL
as	NULL
above	NULL
.	NULL

Plasmids	NULL
and	NULL
Transient	NULL
Transfection	NULL
of	NULL
Jurkat	NULL
Cells	NULL
.	NULL

The	NULL
pIL-2	NULL
5'/Luc	NULL
plasmid	NULL
was	NULL
a	NULL
gift	NULL
of	NULL
G.	NULL
R.	NULL
Crabtree	NULL
(	NULL
Stanford	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
pNFIL-2B/Luc	NULL
was	NULL
made	NULL
by	NULL
cloning	NULL
four	NULL
tandem	NULL
copies	NULL
of	NULL
the	NULL
NFIL-2B	NULL
element	NULL
into	NULL
the	NULL
Xho	NULL
I	NULL
site	NULL
of	NULL
the	NULL
pGL2-promoter	NULL
vector	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

For	NULL
each	NULL
experimental	NULL
point	NULL
,	NULL
2	NULL
x	NULL
10	NULL
``	NULL
Jurkat	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
by	NULL
electroporation	NULL
(	NULL
250	NULL
V	NULL
,	NULL
960	NULL
uF	NULL
)	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
DNA	NULL
,	NULL
pretreated	NULL
and	NULL
activated	NULL
as	NULL
above	NULL
.	NULL

-Galactosidase	NULL
and	NULL
luciferase	NULL
assays	NULL
were	NULL
done	NULL
as	NULL
described	NULL
(	NULL
7	NULL
,	NULL
9	NULL
)	NULL
.	NULL

Fluorescence	NULL
was	NULL
measured	NULL
at	NULL
460	NULL
nm	NULL
using	NULL
355-nm	NULL
excitation	NULL
with	NULL
a	NULL
Perkin-Elmer	NULL
3B	NULL
fluorescence	NULL
spectrometer	NULL
and	NULL
luminescence	NULL
was	NULL
measured	NULL
with	NULL
a	NULL
Moonlight	NULL
2010	NULL
(	NULL
Analytical	NULL
Luminescence	NULL
Laboratory	NULL
,	NULL
San	NULL
Diego	NULL
)	NULL
luminometer	NULL
.	NULL

Preparation	NULL
of	NULL
Nuclear	NULL
Extracts	NULL
and	NULL
Oligonucleotides	NULL
(	NULL
Oli-gos	NULL
)	NULL
.	NULL

Extracts	NULL
of	NULL
cultured	NULL
cells	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
by	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
10	NULL
)	NULL
.	NULL

Single-stranded	NULL
oligos	NULL
were	NULL
chemically	NULL
synthesized	NULL
and	NULL
equimolar	NULL
amounts	NULL
of	NULL
complementary	NULL
strands	NULL
were	NULL
combined	NULL
and	NULL
purified	NULL
on	NULL
15	NULL
%	NULL
PAGE	NULL
.	NULL

The	NULL
NFIL-2B	NULL
probe	NULL
was	NULL
made	NULL
by	NULL
annealing	NULL
oligos	NULL
tcgacAAT-TCCAAAGAGTCATCAGAAGAGGAc	NULL
and	NULL
tegagTCCTCT-TCTGATGACTCTTTGGAATTg	NULL
.	NULL

The	NULL
NFIL2Bm	NULL
probe	NULL
was	NULL
made	NULL
by	NULL
annealing	NULL
oligos	NULL
tcgaCAATTCCAAAGAGTat-TCAGAAGAGGAC	NULL
and	NULL
tegagTCCTCTTCTGAatAC-TCTTTGGAATTg	NULL
.	NULL

The	NULL
AP-1	NULL
probe	NULL
was	NULL
made	NULL
by	NULL
annealing	NULL
oligos	NULL
tegaGTGACTCAGCGCG	NULL
and	NULL
tegaCGCGCTGAGT-CAC	NULL
.	NULL

The	NULL
NF-AT	NULL
probe	NULL
was	NULL
made	NULL
by	NULL
annealing	NULL
oligos	NULL
gatcCATGAAACAGTTTTTCCTCCTTA	NULL
and	NULL
gatcTAAG-GAGGAAAAACTGTTTCATG	NULL
.	NULL

Abbreviations	NULL
:	NULL
IL-2	NULL
,	NULL
interleukin	NULL
2	NULL
;	NULL
IL-4	NULL
,	NULL
interleukin	NULL
4	NULL
;	NULL
IFN-y	NULL
,	NULL
interferon	NULL
y	NULL
;	NULL
PBL	NULL
,	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cell	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-ggﬁg'state	NULL
l3-acetate	NULL
;	NULL
oligo	NULL
,	NULL
oligonucleotide	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
.	NULL

Immunology	NULL
:	NULL
Schwarz	NULL
et	NULL
al	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Nonlabeled	NULL
oligo	NULL
was	NULL
added	NULL
10	NULL
min	NULL
before	NULL
addition	NULL
of	NULL
the	NULL
probe	NULL
in	NULL
competition	NULL
experiments	NULL
.	NULL

c-Jun	NULL
protein	NULL
(	NULL
4	NULL
foot-printing	NULL
units	NULL
,	NULL
Promega	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
nuclear	NULL
extracts	NULL
10	NULL
min	NULL
before	NULL
addition	NULL
of	NULL
the	NULL
probe	NULL
in	NULL
competition	NULL
experiments	NULL
.	NULL

RESULTS	NULL
Suppression	NULL
of	NULL
IL2	NULL
Expression	NULL
by	NULL
IL-4	NULL
.	NULL

Jurkat	NULL
cells	NULL
have	NULL
long	NULL
served	NULL
as	NULL
a	NULL
useful	NULL
human	NULL
T-cell	NULL
model	NULL
for	NULL
study	NULL
of	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
ZL2	NULL
gene	NULL
.	NULL

Stimulation	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
mimics	NULL
the	NULL
effect	NULL
of	NULL
T-cell	NULL
receptor-induced	NULL
activation	NULL
of	NULL
phospholipase	NULL
C	NULL
and	NULL
protein	NULL
kinase	NULL
C	NULL
,	NULL
respectively	NULL
,	NULL
thereby	NULL
inducing	NULL
IL2	NULL
gene	NULL
transcription	NULL
.	NULL

When	NULL
we	NULL
pretreated	NULL
Jurkat	NULL
cells	NULL
with	NULL
IL-4	NULL
,	NULL
an	NULL
80	NULL
%	NULL
decrease	NULL
in	NULL
IL2	NULL
mRNA	NULL
production	NULL
was	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

This	NULL
suppression	NULL
could	NULL
be	NULL
attributed	NULL
entirely	NULL
to	NULL
a	NULL
decrease	NULL
in	NULL
the	NULL
rate	NULL
of	NULL
IL2	NULL
gene	NULL
transcription	NULL
,	NULL
since	NULL
the	NULL
half-life	NULL
of	NULL
the	NULL
mRNA	NULL
was	NULL
unaffected	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

Of	NULL
interest	NULL
,	NULL
addition	NULL
of	NULL
an	NULL
antibody	NULL
to	NULL
CD28	NULL
,	NULL
a	NULL
costimulatory	NULL
signal	NULL
,	NULL
relieved	NULL
this	NULL
suppression	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

To	NULL
ascertain	NULL
the	NULL
biological	NULL
significance	NULL
of	NULL
these	NULL
findings	NULL
with	NULL
the	NULL
Jurkat	NULL
cell	NULL
line	NULL
,	NULL
we	NULL
measured	NULL
the	NULL
effect	NULL
of	NULL
IL-4	NULL
on	NULL
steady-state	NULL
mRNA	NULL
levels	NULL
in	NULL
primary	NULL
PBLs	NULL
.	NULL

Northern	NULL
analysis	NULL
indicated	NULL
that	NULL
the	NULL
transcriptional	NULL
down-regulation	NULL
of	NULL
the	NULL
IL2	NULL
gene	NULL
by	NULL
IL-4	NULL
observed	NULL
in	NULL
Jurkat	NULL
cells	NULL
faithfully	NULL
reflected	NULL
that	NULL
in	NULL
primary	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
these	NULL
experiments	NULL
showed	NULL
that	NULL
the	NULL
IFNG	NULL
gene	NULL
was	NULL
also	NULL
down-regulated	NULL
by	NULL
IL-4	NULL
.	NULL

A	NULL
recent	NULL
study	NULL
in	NULL
mouse	NULL
(	NULL
11	NULL
)	NULL
and	NULL
the	NULL
present	NULL
study	NULL
in	NULL
human	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
demonstrate	NULL
that	NULL
a	NULL
minimum	NULL
of	NULL
12	NULL
hr	NULL
of	NULL
IL-4	NULL
pretreatment	NULL
is	NULL
required	NULL
for	NULL
suppression	NULL
of	NULL
IL2	NULL
mRNA	NULL
levels	NULL
to	NULL
be	NULL
manifest	NULL
.	NULL

IL-4	NULL
Selectively	NULL
Inhibits	NULL
NFIL-2B	NULL
.	NULL

Transcription	NULL
of	NULL
the	NULL
ZL2	NULL
gene	NULL
is	NULL
regulated	NULL
primarily	NULL
through	NULL
the	NULL
5	NULL
'	NULL
flanking	NULL
region	NULL
326	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Since	NULL
many	NULL
of	NULL
the	NULL
binding	NULL
sites	NULL
for	NULL
nuclear	NULL
factors	NULL
in	NULL
this	NULL
region	NULL
are	NULL
known	NULL
(	NULL
13-16	NULL
)	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
assay	NULL
these	NULL
enhancer	NULL
elements	NULL
independently	NULL
to	NULL
determine	NULL
if	NULL
any	NULL
was	NULL
inhibited	NULL
by	NULL
IL-4	NULL
pretreatment	NULL
.	NULL

One	NULL
5	NULL
'	NULL
element	NULL
of	NULL
the	NULL
IL2	NULL
gene	NULL
,	NULL
termed	NULL
NFIL-2B	NULL
,	NULL
originally	NULL
defined	NULL
as	NULL
being	NULL
protected	NULL
from	NULL
DNase	NULL
I	NULL
attack	NULL
upon	NULL
T-cell	NULL
activation	NULL
and	NULL
essential	NULL
to	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
IL2	NULL
gene	NULL
by	NULL
deletion	NULL
analysis	NULL
(	NULL
14	NULL
)	NULL
,	NULL
was	NULL
of	NULL
particular	NULL
interest	NULL
because	NULL
it	NULL
has	NULL
been	NULL
identified	NULL
as	NULL
the	NULL
element	NULL
sensitive	NULL
to	NULL
cyclosporin	NULL
A	NULL
(	NULL
7	NULL
)	NULL
,	NULL
glucocorticoids	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
,	NULL
and	NULL
clonal	NULL
anergy	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Using	NULL
Jurkat	NULL
cells	NULL
transformed	NULL
initially	NULL
with	NULL
a	NULL
series	NULL
of	NULL
integrated	NULL
B-galactosidase	NULL
reporter	NULL
constructs	NULL
,	NULL
we	NULL
found	NULL
the	NULL
NFIL-2B	NULL
enhancer	NULL
element	NULL
was	NULL
reduced	NULL
50	NULL
%	NULL
in	NULL
transcriptional	NULL
activity	NULL
by	NULL
IL-4	NULL
pretreatment	NULL
,	NULL
whereas	NULL
the	NULL
NF-AT	NULL
and	NULL
Oct-1	NULL
enhancer	NULL
elements	NULL
were	NULL
not	NULL
affected	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

The	NULL
NFKB	NULL
enhancer	NULL
element	NULL
was	NULL
slightly	NULL
inhibited	NULL
by	NULL
IL-4	NULL
.	NULL

Since	NULL
the	NULL
IL-4	NULL
effects	NULL
on	NULL
the	NULL
enhancer	NULL
&	NULL
bra	NULL
200	NULL
NS	NULL
O	NULL
>	NULL
J	NULL
{	NULL
P+	NULL
@	NULL
ER	NULL
ica	NULL
24	NULL
hr	NULL
P+1	NULL
IL-2	NULL
<	NULL
Q	NULL
iL-4	NULL
24	NULL
hr	NULL
P+	NULL
CD28	NULL
g	NULL
Z	NULL
CC	NULL
E	NULL
cu	NULL
=	NULL
100	NULL
C	NULL
2	NULL
5	NULL
C	NULL
i	NULL
y-Actin	NULL
6	NULL
so	NULL
0	NULL
o	NULL
I	NULL
P+I	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
(	NULL
1993	NULL
)	NULL
7735	NULL
elements	NULL
did	NULL
not	NULL
reflect	NULL
the	NULL
expected	NULL
results	NULL
based	NULL
on	NULL
the	NULL
experiments	NULL
with	NULL
the	NULL
endogenous	NULL
ZL2	NULL
gene	NULL
,	NULL
we	NULL
reasoned	NULL
that	NULL
this	NULL
was	NULL
due	NULL
to	NULL
position	NULL
effects	NULL
of	NULL
the	NULL
integrated	NULL
reporters	NULL
.	NULL

To	NULL
establish	NULL
that	NULL
the	NULL
IL-4	NULL
effects	NULL
on	NULL
the	NULL
NFIL-2B	NULL
element	NULL
and	NULL
the	NULL
entire	NULL
ZL2	NULL
enhancer	NULL
were	NULL
substantial	NULL
,	NULL
transient	NULL
transfection	NULL
assays	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
luciferase	NULL
reporter	NULL
plasmids	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
clearly	NULL
confirmed	NULL
that	NULL
IL-4	NULL
pretreatment	NULL
prevents	NULL
transcription	NULL
of	NULL
the	NULL
IL2	NULL
gene	NULL
by	NULL
inhibiting	NULL
the	NULL
NFIL-2B	NULL
element	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
NFIL-2B	NULL
enhancer	NULL
activity	NULL
resulting	NULL
from	NULL
IL-4	NULL
pretreatment	NULL
can	NULL
be	NULL
explained	NULL
by	NULL
our	NULL
observation	NULL
that	NULL
the	NULL
NFIL-2B	NULL
complex	NULL
is	NULL
not	NULL
formed	NULL
in	NULL
gel	NULL
shift	NULL
assays	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
IL-4	NULL
prior	NULL
to	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

In	NULL
controls	NULL
we	NULL
observed	NULL
that	NULL
IL-4	NULL
pretreatment	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
complexes	NULL
as	NULL
assayed	NULL
by	NULL
gel	NULL
shifts	NULL
(	NULL
Figs	NULL
.	NULL

4	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

NFIL-2B	NULL
Is	NULL
a	NULL
Transcription	NULL
Factor	NULL
Distinct	NULL
from	NULL
AP-1	NULL
.	NULL

The	NULL
NFIL-2B	NULL
element	NULL
contains	NULL
a	NULL
putative	NULL
AP-1	NULL
binding	NULL
site	NULL
,	NULL
TRE	NULL
(	NULL
AGAGTCA	NULL
)	NULL
,	NULL
and	NULL
it	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
partially	NULL
purified	NULL
AP-1	NULL
will	NULL
bind	NULL
to	NULL
this	NULL
site	NULL
(	NULL
20	NULL
)	NULL
.	NULL

It	NULL
is	NULL
also	NULL
known	NULL
that	NULL
the	NULL
IL2	NULL
gene	NULL
is	NULL
regulated	NULL
by	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
data	NULL
several	NULL
groups	NULL
inferred	NULL
that	NULL
the	NULL
NFIL-2B	NULL
element	NULL
is	NULL
merely	NULL
an	NULL
AP-1	NULL
site	NULL
.	NULL

To	NULL
clarify	NULL
the	NULL
issue	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
factors	NULL
that	NULL
bind	NULL
this	NULL
element	NULL
in	NULL
greater	NULL
detail	NULL
.	NULL

In	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
using	NULL
the	NULL
-159	NULL
to	NULL
-134	NULL
region	NULL
as	NULL
a	NULL
probe	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
,	NULL
two	NULL
complexes	NULL
were	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

54	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

When	NULL
gel	NULL
shifts	NULL
were	NULL
performed	NULL
with	NULL
an	NULL
oligo	NULL
mutated	NULL
in	NULL
the	NULL
two	NULL
major	NULL
AP-1	NULL
contact	NULL
bases	NULL
(	NULL
NFIL-2Bm	NULL
)	NULL
,	NULL
which	NULL
reduces	NULL
its	NULL
capacity	NULL
to	NULL
bind	NULL
AP-1	NULL
>	NULL
100-fold	NULL
(	NULL
22	NULL
)	NULL
,	NULL
only	NULL
the	NULL
lower	NULL
complex	NULL
was	NULL
formed	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Since	NULL
it	NULL
is	NULL
known	NULL
that	NULL
c-Jun	NULL
is	NULL
constitutively	NULL
produced	NULL
,	NULL
but	NULL
that	NULL
c-Fos	NULL
is	NULL
induced	NULL
upon	NULL
stimulation	NULL
(	NULL
23	NULL
)	NULL
,	NULL
this	NULL
finding	NULL
indicates	NULL
that	NULL
in	NULL
unstimulated	NULL
cells	NULL
the	NULL
DNA	NULL
binding	NULL
of	NULL
the	NULL
upper	NULL
complex	NULL
is	NULL
probably	NULL
due	NULL
to	NULL
Jun	NULL
homodimers	NULL
.	NULL

When	NULL
gel	NULL
shifts	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
using	NULL
the	NULL
wild-type	NULL
and	NULL
mutant	NULL
oligos	NULL
,	NULL
only	NULL
the	NULL
lower	NULL
complex	NULL
was	NULL
formed	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
Jun	NULL
homodimer	NULL
complex	NULL
was	NULL
no	NULL
longer	NULL
present	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

Another	NULL
approach	NULL
taken	NULL
to	NULL
discriminate	NULL
different	NULL
DNA	NULL
binding	NULL
proteins	NULL
was	NULL
use	NULL
of	NULL
a	NULL
known	NULL
enhancer	NULL
element	NULL
site	NULL
of	NULL
different	NULL
sequence	NULL
to	NULL
learn	NULL
if	NULL
it	NULL
can	NULL
compete	NULL
in	NULL
a	NULL
gel	NULL
shift	NULL
assay	NULL
.	NULL

We	NULL
used	NULL
an	NULL
unlabeled	NULL
oligomer	NULL
containing	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
human	NULL
metallothionein	NULL
gene	NULL
as	NULL
a	NULL
competitor	NULL
in	NULL
the	NULL
NFIL-2B	NULL
gel	NULL
shift	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
7-13	NULL
)	NULL
.	NULL

If	NULL
the	NULL
only	NULL
function	NULL
of	NULL
the	NULL
NFIL-2B	NULL
element	NULL
were	NULL
to	NULL
bind	NULL
AP-1	NULL
,	NULL
then	NULL
the	NULL
unlabeled	NULL
AP-1	NULL
metallothionine	NULL
oligo	NULL
would	NULL
be	NULL
expected	NULL
to	NULL
competitively	NULL
inhibit	NULL
the	NULL
NFIL-2B	NULL
gel	NULL
shift	NULL
.	NULL

Fig	NULL
.	NULL

5A	NULL
(	NULL
lanes	NULL
8	NULL
,	NULL
11	NULL
,	NULL
and	NULL
13	NULL
)	NULL
demonstrates	NULL
that	NULL
the	NULL
unlabeled	NULL
AP-1	NULL
oligo	NULL
failed	NULL
to	NULL
competitively	NULL
inhibit	NULL
the	NULL
NFIL-2B	NULL
gel	NULL
shift	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
stimulated	NULL
cells	NULL
.	NULL

«	NULL
CD28	NULL
P+I	NULL
¥	NULL
:	NULL
IL-4	NULL
P+I	NULL
FiG	NULL
.	NULL

1	NULL
.	NULL

Effects	NULL
of	NULL
IL-4	NULL
on	NULL
IL-2	NULL
mRNA	NULL
levels	NULL
in	NULL
stimulated	NULL
Jurkat	NULL
cells	NULL
.	NULL

Bars	NULL
represent	NULL
the	NULL
average	NULL
values	NULL
of	NULL
the	NULL
hybridization	NULL
intensities	NULL
of	NULL
three	NULL
Northern	NULL
blots	NULL
.	NULL

IL-2	NULL
mRNA	NULL
levels	NULL
are	NULL
presented	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
the	NULL
mRNA	NULL
levels	NULL
expressed	NULL
in	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
P+1	NULL
.	NULL

Nonstimulated	NULL
(	NULL
NS	NULL
)	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
a	NULL
control	NULL
.	NULL

7736	NULL
Immunology	NULL
:	NULL
Schwarz	NULL
et	NULL
al	NULL
.	NULL

3	NULL
>	NULL
120	NULL
-o-	NULL
P+I	NULL
se	NULL
#	NULL
=	NULL
IL-4	NULL
24	NULL
hr	NULL
P+l	NULL
\_	NULL
==®	NULL
>	NULL
IL-4	NULL
24	NULL
hr	NULL
P+1	NULL
+	NULL
anti-CD28	NULL
s	NULL
[	NULL
=	NULL
]	NULL
O	NULL
Co	NULL
o	NULL
a	NULL
G	NULL
604	NULL
%	NULL
of	NULL
IL2	NULL
mRNA	NULL
before	NULL
B	NULL
2	NULL
addition	NULL
of	NULL
actinomycin	NULL
D	NULL
ho	NULL
O	NULL
O	NULL
o	NULL
-	NULL
20	NULL
-	NULL
40	NULL
_	NULL
60	NULL
=	NULL
so	NULL
100	NULL
Time	NULL
,	NULL
min	NULL
B	NULL
125	NULL
100	NULL
oa	NULL
N	NULL
O	NULL
on	NULL
i	NULL
a	NULL
%	NULL
of	NULL
maximum	NULL
mRNA	NULL
levels	NULL
No	NULL
i	NULL
led	NULL
1	NULL
IL-4	NULL
24	NULL
hr	NULL
IL-4	NULL
24	NULL
hr	NULL
IL2	NULL
IFNG	NULL
None	NULL
P+1	NULL
120	NULL
100	NULL
+	NULL
80	NULL
7	NULL
60	NULL
4	NULL
40	NULL
4	NULL
20	NULL
1	NULL
%	NULL
of	NULL
maximum	NULL
/L2	NULL
mRNA	NULL
levels	NULL
12	NULL
16	NULL
20	NULL
24	NULL
28	NULL
Time	NULL
,	NULL
hr	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
rate	NULL
of	NULL
mRNA	NULL
degradation	NULL
in	NULL
Jurkat	NULL
cells	NULL
stimulated	NULL
for	NULL
6	NULL
hr	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
P+1	NULL
)	NULL
,	NULL
with	NULL
or	NULL
without	NULL
IL-4	NULL
pretreatment	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
anti-CD28	NULL
.	NULL

The	NULL
values	NULL
of	NULL
each	NULL
time	NULL
point	NULL
represent	NULL
the	NULL
average	NULL
of	NULL
the	NULL
hybridization	NULL
intensities	NULL
of	NULL
three	NULL
Northern	NULL
blots	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
%	NULL
of	NULL
the	NULL
mRNA	NULL
level	NULL
at	NULL
time	NULL
zero	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Effects	NULL
of	NULL
IL-4	NULL
on	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
mRNA	NULL
levels	NULL
in	NULL
PBLs	NULL
.	NULL

Bars	NULL
represent	NULL
the	NULL
average	NULL
of	NULL
two	NULL
and	NULL
three	NULL
experiments	NULL
,	NULL
respectively	NULL
.	NULL

None	NULL
,	NULL
no	NULL
stimulation	NULL
;	NULL
P+I	NULL
,	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Time	NULL
course	NULL
of	NULL
IL-4	NULL
suppression	NULL
of	NULL
IL-2	NULL
mRNA	NULL
levels	NULL
.	NULL

Each	NULL
time	NULL
point	NULL
represents	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

These	NULL
two	NULL
sets	NULL
of	NULL
experiments	NULL
together	NULL
provide	NULL
compelling	NULL
evidence	NULL
that	NULL
the	NULL
DNA	NULL
binding	NULL
in	NULL
the	NULL
NFIL-2B	NULL
complex	NULL
is	NULL
not	NULL
mediated	NULL
by	NULL
AP-1	NULL
.	NULL

It	NULL
was	NULL
surprising	NULL
that	NULL
the	NULL
NFIL-2B	NULL
gel	NULL
shift	NULL
was	NULL
generated	NULL
when	NULL
the	NULL
unlabeled	NULL
AP-1	NULL
oligo	NULL
was	NULL
added	NULL
to	NULL
extracts	NULL
from	NULL
unstimulated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
7	NULL
,	NULL
10	NULL
,	NULL
and	NULL
12	NULL
)	NULL
.	NULL

This	NULL
result	NULL
suggested	NULL
that	NULL
in	NULL
unstimulated	NULL
cells	NULL
,	NULL
the	NULL
NFIL-2B	NULL
factor	NULL
may	NULL
be	NULL
bound	NULL
to	NULL
an	NULL
inhibitor	NULL
that	NULL
prevents	NULL
it	NULL
from	NULL
binding	NULL
DNA	NULL
.	NULL

The	NULL
putative	NULL
inhibitor	NULL
could	NULL
specifically	NULL
interact	NULL
with	NULL
the	NULL
AP-1	NULL
oligo	NULL
and	NULL
,	NULL
in	NULL
so	NULL
doing	NULL
,	NULL
allow	NULL
the	NULL
NFIL-2B	NULL
complex	NULL
to	NULL
form	NULL
.	NULL

The	NULL
same	NULL
experiments	NULL
also	NULL
revealed	NULL
that	NULL
the	NULL
NFIL-2B	NULL
factor	NULL
is	NULL
constitutively	NULL
expressed	NULL
but	NULL
is	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
DNA	NULL
only	NULL
after	NULL
cells	NULL
are	NULL
stimulated	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
the	NULL
IL-4-pretreated	NULL
and	NULL
stimulated	NULL
cells	NULL
yielded	NULL
the	NULL
same	NULL
results	NULL
as	NULL
those	NULL
from	NULL
unstimulated	NULL
cells	NULL
,	NULL
a	NULL
weak	NULL
NFIL-2B	NULL
gel	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
(	NULL
1993	NULL
)	NULL
sk	NULL
to	NULL
o	NULL
100	NULL
m	NULL
None	NULL
80	NULL
60	NULL
o	NULL
P+	NULL
404	NULL
@	NULL
IL-4	NULL
24	NULL
hr	NULL
P+	NULL
%	NULL
maximal	NULL
B-galactosidase	NULL
activity	NULL
B	NULL
6000	NULL
3000	NULL
5000	NULL
s	NULL
2000	NULL
4000	NULL
F	NULL
3	NULL
*	NULL
3000	NULL
T	NULL
1000	NULL
2000	NULL
1000	NULL
0	NULL
No	NULL
P+1	NULL
IL-2	NULL
-	NULL
IL-4	NULL
5'/Luc	NULL
24	NULL
hr	NULL
Vector	NULL
-	NULL
NFIL-	NULL
IL-4	NULL
2B/Luc	NULL
24	NULL
hr	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

(	NULL
A4	NULL
)	NULL
Effects	NULL
of	NULL
IL-4	NULL
pretreatment	NULL
on	NULL
the	NULL
IL2	NULL
enhancer	NULL
elements	NULL
fused	NULL
to	NULL
a	NULL
B-galactosidase	NULL
reporter	NULL
activity	NULL
in	NULL
transfected	NULL
Jurkat	NULL
cells	NULL
.	NULL

Oct	NULL
1	NULL
,	NULL
lacZ	NULL
transcription	NULL
with	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
NFIL-2A	NULL
binding	NULL
region	NULL
(	NULL
-93	NULL
to	NULL
-65	NULL
)	NULL
linked	NULL
to	NULL
a	NULL
minimal	NULL
yfibrin-ogen	NULL
promoter	NULL
;	NULL
NFIL-2B	NULL
,	NULL
lacZ	NULL
transcription	NULL
with	NULL
four	NULL
copies	NULL
of	NULL
NFIL-2B	NULL
binding	NULL
region	NULL
(	NULL
-159	NULL
to	NULL
-134	NULL
)	NULL
linked	NULL
to	NULL
the	NULL
IL2	NULL
promoter	NULL
(	NULL
-72	NULL
to	NULL
+45	NULL
)	NULL
;	NULL
NFkB	NULL
,	NULL
lacZ	NULL
transcription	NULL
with	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
NFkB	NULL
site	NULL
of	NULL
the	NULL
mouse	NULL
x	NULL
light	NULL
chain	NULL
gene	NULL
linked	NULL
to	NULL
the	NULL
IL2	NULL
promoters	NULL
;	NULL
NF-AT	NULL
,	NULL
lacZ	NULL
transcription	NULL
with	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
NF-AT	NULL
binding	NULL
site	NULL
(	NULL
-286	NULL
to	NULL
-257	NULL
)	NULL
linked	NULL
to	NULL
the	NULL
ZL2	NULL
promoter	NULL
.	NULL

The	NULL
bars	NULL
represent	NULL
the	NULL
mean	NULL
B-galactosidase	NULL
activities	NULL
of	NULL
three	NULL
experiments	NULL
,	NULL
calculated	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
the	NULL
maximal	NULL
activity	NULL
of	NULL
each	NULL
cell	NULL
line	NULL
after	NULL
stimulation	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
P+1	NULL
)	NULL
.	NULL

None	NULL
,	NULL
no	NULL
stimulation	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Effects	NULL
of	NULL
IL-4	NULL
pretreatment	NULL
on	NULL
the	NULL
NFIL-2B	NULL
and	NULL
IL-2	NULL
5	NULL
'	NULL
enhancers	NULL
assayed	NULL
by	NULL
transient	NULL
transfection	NULL
luciferase	NULL
assays	NULL
.	NULL

The	NULL
bars	NULL
represent	NULL
the	NULL
average	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

The	NULL
pGL-2	NULL
promoter	NULL
vector	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
for	NULL
NFIL-2B	NULL
,	NULL
and	NULL
unstimulated	NULL
transfected	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
a	NULL
control	NULL
for	NULL
IL-2	NULL
5	NULL
'	NULL
.	NULL

RLU	NULL
,	NULL
relative	NULL
light	NULL
units	NULL
.	NULL

shift	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
4	NULL
)	NULL
,	NULL
unless	NULL
the	NULL
unlabeled	NULL
AP-1	NULL
oligo	NULL
was	NULL
added	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
9	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
IL-4	NULL
pretreatment	NULL
does	NULL
not	NULL
prevent	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
NFIL-2B	NULL
factor	NULL
but	NULL
blocks	NULL
some	NULL
modification	NULL
that	NULL
enables	NULL
it	NULL
to	NULL
bind	NULL
DNA	NULL
following	NULL
stimulation	NULL
.	NULL

As	NULL
predicted	NULL
by	NULL
the	NULL
inhibitor	NULL
model	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
unlabeled	NULL
AP-1	NULL
oligo	NULL
to	NULL
generate	NULL
the	NULL
NFIL-2B	NULL
gel	NULL
shift	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
unstimulated	NULL
cells	NULL
was	NULL
concentration	NULL
dependent	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

Less	NULL
than	NULL
20	NULL
ng	NULL
of	NULL
unlabeled	NULL
oligo	NULL
was	NULL
insufficient	NULL
to	NULL
liberate	NULL
NFIL-2B	NULL
and	NULL
>	NULL
20	NULL
ug	NULL
of	NULL
oligo	NULL
nonspecifically	NULL
inhibited	NULL
the	NULL
NFIL-2B	NULL
gel	NULL
shift	NULL
.	NULL

We	NULL
then	NULL
tested	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
inhibitor	NULL
might	NULL
be	NULL
c-Jun	NULL
.	NULL

The	NULL
NFIL-2B	NULL
DNA	NULL
complex	NULL
generated	NULL
with	NULL
unstimulated	NULL
nuclear	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
was	NULL
dissociated	NULL
and	NULL
competitively	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
purified	NULL
c-Jun	NULL
homodimers	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
but	NULL
not	NULL
20	NULL
ug	NULL
of	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
an	NULL
irrelevant	NULL
protein	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DISCUSSION	NULL
The	NULL
data	NULL
of	NULL
the	NULL
present	NULL
study	NULL
clearly	NULL
indicate	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
DNA	NULL
binding	NULL
factor	NULL
distinct	NULL
from	NULL
AP-1	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
sequence	NULL
defined	NULL
by	NULL
Durand	NULL
et	NULL
al	NULL
.	NULL

(	NULL
14	NULL
)	NULL
as	NULL
NFIL-2B	NULL
and	NULL
that	NULL
is	NULL
present	NULL
in	NULL
resting	NULL
and	NULL
stimulated	NULL
T-cell	NULL
,	NULL
B-cell	NULL
,	NULL
and	NULL
mac-rophage	NULL
cell	NULL
lines	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

The	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
a	NULL
Immunology	NULL
:	NULL
Schwarz	NULL
et	NULL
al	NULL
.	NULL

B	NULL
IL-4	NULL
A	NULL
G	NULL
-1	NULL
OP	NULL
igo	NULL
anc	NULL
A	NULL
PMA	NULL
+	NULL
-4	NULL
NFIL-2B	NULL
*p	NULL
Cold	NULL
NFIL-2B	NULL
Lane	NULL
NFIL-2B	NULL
Free	NULL
Oligo	NULL
Pretreatment	NULL
Free	NULL
Oligo	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
(	NULL
1993	NULL
)	NULL
7737	NULL
C	NULL
Nuclear	NULL
Extract	NULL
IL-4	NULL
Pretreatment	NULL
mal	NULL
NF-AT	NULL
Oligo	NULL
*P	NULL
+	NULL
Cold	NULL
NF-AT	NULL
Oligo	NULL
=	NULL
Lane	NULL
1	NULL
oll	NULL
|+	NULL
]	NULL
1	NULL
|+	NULL
®	NULL
||	NULL
|+	NULL
|+	NULL
|	NULL
+	NULL
O	NULL
Io	NULL
|+	NULL
]	NULL
+	NULL
[	NULL
|	NULL
[	NULL
(	NULL
+	NULL
NF-AT	NULL
Free	NULL
Oligo	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Effects	NULL
of	NULL
IL-4	NULL
on	NULL
NFIL-2B	NULL
(	NULL
4	NULL
)	NULL
,	NULL
AP-1	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
NF-AT	NULL
(	NULL
C	NULL
)	NULL
,	NULL
as	NULL
assayed	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
.	NULL

(	NULL
4	NULL
)	NULL
The	NULL
weak	NULL
NFIL-2B	NULL
DNA	NULL
binding	NULL
in	NULL
unstimulated	NULL
cells	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
is	NULL
enhanced	NULL
upon	NULL
activation	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

The	NULL
gel	NULL
shift	NULL
is	NULL
competitively	NULL
inhibited	NULL
with	NULL
unlabeled	NULL
NFIL-2B	NULL
oligo	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

This	NULL
enhancement	NULL
is	NULL
prevented	NULL
in	NULL
IL-4-pretreated	NULL
cells	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Lane	NULL
5	NULL
,	NULL
oligo	NULL
alone	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
AP-1	NULL
gel	NULL
shift	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
6	NULL
)	NULL
could	NULL
be	NULL
competitively	NULL
inhibited	NULL
with	NULL
unlabeled	NULL
AP-1	NULL
oligo	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
and	NULL
5	NULL
)	NULL
and	NULL
was	NULL
unaffected	NULL
by	NULL
IL-4	NULL
pretreatment	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Oligo	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

The	NULL
NF-AT	NULL
gel	NULL
shift	NULL
from	NULL
stimulated	NULL
nuclear	NULL
extracts	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
could	NULL
be	NULL
competitively	NULL
inhibited	NULL
with	NULL
unlabeled	NULL
NF-AT	NULL
oligo	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
and	NULL
was	NULL
unaffected	NULL
by	NULL
IL-4	NULL
pretreatment	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

model	NULL
in	NULL
which	NULL
NFIL-2B	NULL
in	NULL
resting	NULL
cells	NULL
is	NULL
bound	NULL
to	NULL
an	NULL
inhibitor	NULL
,	NULL
most	NULL
probably	NULL
Jun	NULL
homodimers	NULL
,	NULL
and	NULL
is	NULL
not	NULL
free	NULL
to	NULL
bind	NULL
the	NULL
enhancer	NULL
until	NULL
c-Fos	NULL
is	NULL
induced	NULL
by	NULL
stimulation	NULL
and	NULL
the	NULL
AP-1	NULL
heterodimer	NULL
forms	NULL
,	NULL
or	NULL
a	NULL
post-translational	NULL
modification	NULL
releases	NULL
the	NULL
factor	NULL
.	NULL

There	NULL
are	NULL
multiple	NULL
additional	NULL
lines	NULL
of	NULL
evidence	NULL
consistent	NULL
with	NULL
our	NULL
interpretation	NULL
that	NULL
the	NULL
NFIL-2B	NULL
factor	NULL
is	NULL
distinct	NULL
from	NULL
AP-1	NULL
and	NULL
essential	NULL
for	NULL
IL2	NULL
gene	NULL
regulation	NULL
:	NULL
(	NULL
?	NULL
)	NULL

the	NULL
-159	NULL
to	NULL
-151	NULL
deletion	NULL
mutant	NULL
,	NULL
which	NULL
leaves	NULL
a	NULL
putative	NULL
AP-1	NULL
binding	NULL
site	NULL
intact	NULL
,	NULL
exhibits	NULL
an	NULL
89	NULL
%	NULL
loss	NULL
of	NULL
transcription	NULL
(	NULL
14	NULL
)	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
the	NULL
core	NULL
AP-1-like	NULL
sequence	NULL
of	NULL
the	NULL
NFIL-2B	NULL
site	NULL
,	NULL
AGAGTCA	NULL
,	NULL
does	NULL
not	NULL
bind	NULL
Jun/Fos	NULL
het-erodimers	NULL
(	NULL
24	NULL
)	NULL
;	NULL
(	NULL
ii	NULL
?	NULL
)	NULL

the	NULL
transversion	NULL
of	NULL
the	NULL
T	NULL
in	NULL
the	NULL
first	NULL
position	NULL
of	NULL
the	NULL
putative	NULL
AP-1	NULL
site	NULL
in	NULL
the	NULL
NFIL-2B	NULL
element	NULL
results	NULL
in	NULL
the	NULL
total	NULL
loss	NULL
of	NULL
AP-1	NULL
transactivation	NULL
by	NULL
this	NULL
element	NULL
A	NULL
RaJi_	NULL
U937	NULL
f	NULL
roar	NULL
[	NULL
11	NULL
2p	NULL
B	NULL
ae	NULL
3	NULL
IL-4	NULL
Pretreated	NULL
cold	NULL
NFIL-2B	NULL
oligo	NULL
cold	NULL
AP-1	NULL
oligo	NULL
Upper	NULL
band	NULL
_	NULL
,	NULL
.	NULL

Lower	NULL
band	NULL
--	NULL
»	NULL
Cold	NULL
AP-1	NULL
Oligo	NULL
Added	NULL
to	NULL
Nuclear	NULL
Extracts	NULL
NFIL-2B	NULL
(	NULL
25	NULL
)	NULL
;	NULL
(	NULL
iv	NULL
)	NULL
from	NULL
crystallographic	NULL
data	NULL
the	NULL
conserved	NULL
methyl	NULL
group	NULL
from	NULL
an	NULL
alanine	NULL
residue	NULL
found	NULL
in	NULL
all	NULL
TRE	NULL
binding	NULL
bZIP	NULL
proteins	NULL
,	NULL
including	NULL
Fos	NULL
and	NULL
Jun	NULL
,	NULL
can	NULL
bind	NULL
only	NULL
to	NULL
a	NULL
T	NULL
in	NULL
the	NULL
consensus	NULL
sequence	NULL
,	NULL
and	NULL
not	NULL
an	NULL
A	NULL
as	NULL
found	NULL
in	NULL
NFIL-2B	NULL
(	NULL
26	NULL
)	NULL
;	NULL
(	NULL
v	NULL
)	NULL
activation	NULL
of	NULL
the	NULL
NFIL-2B	NULL
site	NULL
in	NULL
vivo	NULL
requires	NULL
stimulation	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
whereas	NULL
a	NULL
construct	NULL
containing	NULL
a	NULL
consensus	NULL
AP-1	NULL
site	NULL
is	NULL
inducible	NULL
with	NULL
PMA	NULL
alone	NULL
(	NULL
7	NULL
)	NULL
;	NULL
(	NULL
vi	NULL
)	NULL
the	NULL
NFIL-2B	NULL
enhancer	NULL
is	NULL
sensitive	NULL
to	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
,	NULL
whereas	NULL
the	NULL
AP-1	NULL
is	NULL
not	NULL
(	NULL
7	NULL
)	NULL
;	NULL
(	NULL
vii	NULL
)	NULL
largely	NULL
overlooked	NULL
evidence	NULL
indicates	NULL
that	NULL
the	NULL
NFIL-2B	NULL
enhancer	NULL
,	NULL
and	NULL
not	NULL
AP-1	NULL
binding	NULL
,	NULL
is	NULL
depressed	NULL
in	NULL
anergic	NULL
T	NULL
cells	NULL
(	NULL
27	NULL
)	NULL
;	NULL
and	NULL
(	NULL
viii	NULL
)	NULL
as	NULL
we	NULL
have	NULL
demonstrated	NULL
here	NULL
,	NULL
the	NULL
NFIL-2B	NULL
gel	NULL
shift	NULL
is	NULL
sensitive	NULL
to	NULL
IL-4	NULL
pretreatment	NULL
,	NULL
whereas	NULL
the	NULL
AP-1	NULL
gel	NULL
shift	NULL
is	NULL
not	NULL
.	NULL

These	NULL
data	NULL
argue	NULL
that	NULL
the	NULL
factor	NULL
that	NULL
is	NULL
important	NULL
for	NULL
transcription	NULL
of	NULL
the	NULL
C	NULL
Nuclear	NULL
Extract	NULL
]	NULL
-|	NULL
+	NULL
Cold	NULL
AP-1	NULL
Oligo	NULL
_I+	NULL
%	NULL
+	NULL
C-Junl	NULL
~	NULL
]	NULL
-|	NULL
+	NULL
l4	NULL
|+	NULL
4	NULL
20ug	NULL
C-Jun-NFIL-2B	NULL
FiG	NULL
.	NULL

5	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
with	NULL
the	NULL
NFIL-2B	NULL
element	NULL
site	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
unstimulated	NULL
and	NULL
stimulated	NULL
Jurkat	NULL
cells	NULL
were	NULL
used	NULL
in	NULL
gel	NULL
shift	NULL
assays	NULL
with	NULL
radiolabeled	NULL
NFIL-2B	NULL
and	NULL
mutated	NULL
NFIL-2Bm	NULL
oligos	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
two	NULL
protein-DNA	NULL
complexes	NULL
(	NULL
upper	NULL
and	NULL
lower	NULL
)	NULL
are	NULL
indicated	NULL
.	NULL

Unlabeled	NULL
AP-1	NULL
oligo	NULL
was	NULL
also	NULL
used	NULL
to	NULL
identify	NULL
the	NULL
NFIL-2B	NULL
complex	NULL
in	NULL
unstimulated	NULL
and	NULL
stimulated	NULL
Jurkat	NULL
,	NULL
Raji	NULL
,	NULL
and	NULL
U937	NULL
cells	NULL
.	NULL

Due	NULL
to	NULL
the	NULL
disparity	NULL
in	NULL
band	NULL
intensities	NULL
,	NULL
three	NULL
exposure	NULL
times	NULL
were	NULL
used	NULL
:	NULL
lanes	NULL
1-3	NULL
,	NULL
72	NULL
hr	NULL
;	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
,	NULL
24	NULL
hr	NULL
;	NULL
and	NULL
lanes	NULL
6-13	NULL
,	NULL
2	NULL
hr	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
generation	NULL
of	NULL
the	NULL
NFIL-2B	NULL
gel	NULL
shift	NULL
in	NULL
unstimulated	NULL
nuclear	NULL
extracts	NULL
is	NULL
concentration	NULL
dependent	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Prevention	NULL
of	NULL
NFIL-2B	NULL
complex	NULL
formation	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
purified	NULL
c-Jun	NULL
protein	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
oligo	NULL
alone	NULL
.	NULL

The	NULL
very	NULL
intense	NULL
NFIL-2B	NULL
gel	NULL
shift	NULL
complex	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
generated	NULL
by	NULL
adding	NULL
stimulated	NULL
nuclear	NULL
extracts	NULL
to	NULL
radiolabeled	NULL
NFIL-2B	NULL
oligo	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
unlabeled	NULL
AP-1	NULL
oligo	NULL
,	NULL
was	NULL
not	NULL
formed	NULL
when	NULL
c-Jun	NULL
protein	NULL
was	NULL
added	NULL
to	NULL
the	NULL
nuclear	NULL
extract	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
the	NULL
probe	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Lane	NULL
5	NULL
,	NULL
labeled	NULL
and	NULL
unlabeled	NULL
oligos	NULL
alone	NULL
.	NULL

7738	NULL
Immunology	NULL
:	NULL
Schwarz	NULL
et	NULL
al	NULL
.	NULL

IL2	NULL
gene	NULL
and	NULL
binds	NULL
to	NULL
the	NULL
NFIL-2B	NULL
enhancer	NULL
element	NULL
is	NULL
distinct	NULL
from	NULL
AP-1	NULL
.	NULL

It	NULL
has	NULL
also	NULL
been	NULL
found	NULL
that	NULL
the	NULL
NF-AT	NULL
and	NULL
NFIL-2B	NULL
elements	NULL
act	NULL
synergistically	NULL
(	NULL
17	NULL
)	NULL
and	NULL
both	NULL
elements	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
interact	NULL
with	NULL
AP-1-like	NULL
factors	NULL
(	NULL
28-30	NULL
)	NULL
.	NULL

However	NULL
,	NULL
since	NULL
the	NULL
DNA	NULL
binding	NULL
proteins	NULL
that	NULL
recognized	NULL
these	NULL
elements	NULL
are	NULL
distinct	NULL
from	NULL
AP-1	NULL
,	NULL
a	NULL
model	NULL
is	NULL
suggested	NULL
in	NULL
which	NULL
the	NULL
NF-AT	NULL
and	NULL
NFIL-2B	NULL
elements	NULL
,	NULL
both	NULL
essential	NULL
for	NULL
IL2	NULL
transcription	NULL
,	NULL
may	NULL
interact	NULL
by	NULL
binding	NULL
the	NULL
c-Jun	NULL
and	NULL
c-Fos	NULL
components	NULL
of	NULL
AP-1	NULL
,	NULL
perhaps	NULL
after	NULL
its	NULL
phosphorylation	NULL
(	NULL
31	NULL
)	NULL
following	NULL
T-cell	NULL
activation	NULL
,	NULL
to	NULL
form	NULL
a	NULL
transcriptional	NULL
complex	NULL
,	NULL
similar	NULL
to	NULL
the	NULL
original	NULL
proposal	NULL
for	NULL
AP-1	NULL
transcriptional	NULL
activation	NULL
(	NULL
32	NULL
)	NULL
.	NULL

The	NULL
interaction	NULL
of	NULL
all	NULL
three	NULL
factors	NULL
could	NULL
best	NULL
be	NULL
accomplished	NULL
by	NULL
a	NULL
loop	NULL
,	NULL
suggested	NULL
in	NULL
other	NULL
systems	NULL
to	NULL
explain	NULL
how	NULL
enhancing	NULL
elements	NULL
situated	NULL
at	NULL
a	NULL
distance	NULL
from	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
act	NULL
to	NULL
regulate	NULL
transcription	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
.	NULL

The	NULL
CD28	NULL
signal	NULL
may	NULL
relieve	NULL
the	NULL
IL-4-induced	NULL
suppres-sion	NULL
,	NULL
possibly	NULL
by	NULL
stabilizing	NULL
IL2	NULL
transcripts	NULL
(	NULL
35	NULL
)	NULL
or	NULL
by	NULL
compensating	NULL
for	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
NFIL-2B	NULL
complex	NULL
by	NULL
the	NULL
CD28-induced	NULL
nuclear	NULL
factor	NULL
,	NULL
CD28RC	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
the	NULL
site	NULL
precisely	NULL
adjacent	NULL
to	NULL
the	NULL
NFIL-2B	NULL
binding	NULL
site	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Mechanisms	NULL
of	NULL
peripheral	NULL
tolerance-T	NULL
-cell	NULL
suppression	NULL
and	NULL
clonal	NULL
anergy-appear	NULL
to	NULL
share	NULL
many	NULL
similarities	NULL
.	NULL

Our	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
ZL2	NULL
gene	NULL
by	NULL
IL-4	NULL
is	NULL
very	NULL
similar	NULL
to	NULL
that	NULL
recently	NULL
described	NULL
in	NULL
anergic	NULL
T	NULL
cells	NULL
(	NULL
19	NULL
)	NULL
.	NULL

As	NULL
in	NULL
anergy	NULL
,	NULL
IL-4	NULL
pretreatment	NULL
did	NULL
not	NULL
block	NULL
the	NULL
induction	NULL
of	NULL
c-fos	NULL
mRNA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
precise	NULL
molecular	NULL
mechanism	NULL
by	NULL
which	NULL
the	NULL
NFIL-2B	NULL
enhancer	NULL
is	NULL
negatively	NULL
regulated	NULL
in	NULL
all	NULL
of	NULL
these	NULL
systems	NULL
remains	NULL
to	NULL
be	NULL
elucidated	NULL
,	NULL
our	NULL
data	NULL
indicate	NULL
that	NULL
IL-4	NULL
does	NULL
not	NULL
affect	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
NFIL-2B	NULL
factor	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

Thus	NULL
possible	NULL
mechanisms	NULL
of	NULL
suppression	NULL
could	NULL
be	NULL
through	NULL
post-translational	NULL
modifications	NULL
,	NULL
as	NULL
described	NULL
for	NULL
other	NULL
transcription	NULL
factors	NULL
(	NULL
36	NULL
)	NULL
,	NULL
or	NULL
induction	NULL
of	NULL
a	NULL
novel	NULL
factor	NULL
yet	NULL
to	NULL
be	NULL
identified	NULL
.	NULL

Overall	NULL
,	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
one	NULL
mechanism	NULL
by	NULL
which	NULL
IL-4	NULL
down-regulates	NULL
IL-2	NULL
production	NULL
is	NULL
by	NULL
inhibition	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
complex	NULL
,	NULL
NFIL-2B	NULL
.	NULL

The	NULL
complete	NULL
role	NULL
of	NULL
IL-4	NULL
in	NULL
regulation	NULL
of	NULL
T-cell	NULL
subsets	NULL
remains	NULL
to	NULL
be	NULL
elucidated	NULL
.	NULL

It	NULL
is	NULL
clear	NULL
that	NULL
IL-4	NULL
inhibits	NULL
the	NULL
expression	NULL
of	NULL
protective	NULL
cell-mediated	NULL
immunity	NULL
in	NULL
several	NULL
infectious	NULL
disease	NULL
models	NULL
.	NULL

Not	NULL
only	NULL
may	NULL
IL-4	NULL
serve	NULL
as	NULL
a	NULL
growth	NULL
factor	NULL
for	NULL
type	NULL
2	NULL
CD4	NULL
(	NULL
Th2	NULL
)	NULL
ceils	NULL
(	NULL
37	NULL
,	NULL
38	NULL
)	NULL
,	NULL
and	NULL
suppress	NULL
functions	NULL
of	NULL
type	NULL
1	NULL
CD4	NULL
(	NULL
Th1	NULL
)	NULL
cells	NULL
,	NULL
but	NULL
it	NULL
also	NULL
may	NULL
act	NULL
to	NULL
suppress	NULL
the	NULL
differentiation	NULL
of	NULL
virgin	NULL
T	NULL
cells	NULL
to	NULL
type	NULL
1	NULL
T	NULL
cells	NULL
by	NULL
inhibiting	NULL
production	NULL
of	NULL
IL-2	NULL
required	NULL
for	NULL
their	NULL
expansion	NULL
.	NULL

We	NULL
are	NULL
very	NULL
grateful	NULL
to	NULL
Dr.	NULL
P.	NULL
Trotta	NULL
and	NULL
Schering	NULL
for	NULL
the	NULL
generous	NULL
gift	NULL
of	NULL
IL-4	NULL
,	NULL
L.	NULL
A.	NULL
Herzenberg	NULL
and	NULL
J.	NULL
Johnsen	NULL
for	NULL
kindly	NULL
providing	NULL
the	NULL
lacZ	NULL
Jurkat	NULL
lines	NULL
,	NULL
and	NULL
Dr.	NULL
G.	NULL
R.	NULL
Crabtree	NULL
for	NULL
the	NULL
luciferase	NULL
reporters	NULL
as	NULL
well	NULL
as	NULL
helpful	NULL
advice	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
L.	NULL
Leinwand	NULL
,	NULL
W.	NULL
Paul	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
for	NULL
helpful	NULL
comments	NULL
on	NULL
this	NULL
work	NULL
.	NULL

This	NULL
research	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grant	NULL
AI-07118	NULL
.	NULL

1	NULL
.	NULL

Janeway	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Cardings	NULL
,	NULL
S.	NULL
,	NULL
Jones	NULL
,	NULL
B.	NULL
,	NULL
Murray	NULL
,	NULL
J.	NULL
,	NULL
Portoles	NULL
,	NULL
P.	NULL
&	NULL
Bottomly	NULL
,	NULL
K.	NULL
(	NULL
1988	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

101	NULL
,	NULL
39-80	NULL
.	NULL

2	NULL
.	NULL

Mossman	NULL
,	NULL
T.	NULL
R.	NULL
&	NULL
Coffman	NULL
,	NULL
R.	NULL
L.	NULL
(	NULL
1989	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

7	NULL
,	NULL
145-173	NULL
.	NULL

3	NULL
.	NULL

Salgame	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
Abrams	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Clayberger	NULL
,	NULL
C.	NULL
,	NULL
Goldstein	NULL
,	NULL
H.	NULL
,	NULL
Convit	NULL
,	NULL
J.	NULL
,	NULL
Modlin	NULL
,	NULL
R.	NULL
L.	NULL
&	NULL
Bloom	NULL
,	NULL
B.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Science	NULL
254	NULL
,	NULL
279-282	NULL
.	NULL

4	NULL
.	NULL

Sadick	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
Heinzel	NULL
,	NULL
F.	NULL
P.	NULL
,	NULL
Holaday	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
Pu	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
Dawkins	NULL
,	NULL
R.	NULL
S.	NULL
&	NULL
Locksley	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

171	NULL
,	NULL
115-127	NULL
.	NULL

5	NULL
.	NULL

Pearce	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
Caspar	NULL
,	NULL
P.	NULL
,	NULL
Grzych	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Lewis	NULL
,	NULL
F.	NULL
A	NULL
.	NULL

&	NULL
Sher	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

173	NULL
,	NULL
159-166	NULL
.	NULL

6	NULL
.	NULL

Yamamura	NULL
,	NULL
M.	NULL
,	NULL
Uyemura	NULL
,	NULL
K.	NULL
,	NULL
Deans	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
Weinberg	NULL
,	NULL
K.	NULL
,	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
(	NULL
1993	NULL
)	NULL
Rea	NULL
,	NULL
T.	NULL
H.	NULL
,	NULL
Bloom	NULL
,	NULL
B.	NULL
R.	NULL
&	NULL
Modlin	NULL
,	NULL
R.	NULL
L.	NULL
(	NULL
1991	NULL
)	NULL
Science	NULL
254	NULL
,	NULL
277-279	NULL
.	NULL

Mattila	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Fiering	NULL
,	NULL
S.	NULL
,	NULL
Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
McCutcheon	NULL
,	NULL
M.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
&	NULL
Herzenberg	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

9	NULL
,	NULL
4425-4433	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
Fritsch	NULL
,	NULL
E.	NULL
F.	NULL
&	NULL
Maniatis	NULL
,	NULL
T.	NULL
L.	NULL
(	NULL
1989	NULL
)	NULL
Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
(	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Lab	NULL
.	NULL

Press	NULL
,	NULL
Plainview	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Brasier	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
Tate	NULL
,	NULL
J.	NULL
E.	NULL
&	NULL
Habener	NULL
,	NULL
J.	NULL
F.	NULL
(	NULL
1989	NULL
)	NULL
BioTech-niques	NULL
7	NULL
,	NULL
1116-1122	NULL
.	NULL

Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Lebovitz	NULL
,	NULL
R.	NULL
M.	NULL
&	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1983	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11	NULL
,	NULL
1475-1489	NULL
.	NULL

Tanaka	NULL
,	NULL
T.	NULL
,	NULL
Hu-Li	NULL
,	NULL
J.	NULL
,	NULL
Seder	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
de	NULL
St.	NULL
Groth	NULL
,	NULL
B.	NULL
F.	NULL
&	NULL
Paul	NULL
,	NULL
W.	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
,	NULL
5914-5918	NULL
.	NULL

Fujita	NULL
,	NULL
T.	NULL
,	NULL
Shibuya	NULL
,	NULL
H.	NULL
,	NULL
Ohashi	NULL
,	NULL
T.	NULL
,	NULL
Yamanishi	NULL
,	NULL
K.	NULL
&	NULL
Tanigu-chi	NULL
,	NULL
T.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
46	NULL
,	NULL
401-407	NULL
.	NULL

Siebenlist	NULL
,	NULL
U.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Bressler	NULL
,	NULL
P.	NULL
,	NULL
Holbrook	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Norris	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Kamoun	NULL
,	NULL
M.	NULL
,	NULL
Kant	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1986	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

6	NULL
,	NULL
3042-3049	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Shaw	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Bush	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Replogle	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Belagaje	NULL
,	NULL
R.	NULL
&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
1715-1724	NULL
.	NULL

Hoyos	NULL
,	NULL
B.	NULL
,	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Bohnlein	NULL
,	NULL
E.	NULL
,	NULL
Siekevitz	NULL
,	NULL
M.	NULL
&	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
244	NULL
,	NULL
457-460	NULL
.	NULL

Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Irving	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
&	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Science	NULL
251	NULL
,	NULL
313-316	NULL
.	NULL

Vacca	NULL
,	NULL
A.	NULL
,	NULL
Felli	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Farina	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
Martinotti	NULL
,	NULL
S.	NULL
,	NULL
Maroder	NULL
,	NULL
M.	NULL
,	NULL
Screpanti	NULL
,	NULL
I.	NULL
,	NULL
Meco	NULL
,	NULL
D.	NULL
,	NULL
Petrangeli	NULL
,	NULL
E.	NULL
,	NULL
Frati	NULL
,	NULL
L.	NULL
&	NULL
Gulino	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175	NULL
,	NULL
637-646	NULL
.	NULL

Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
&	NULL
Mattila	NULL
,	NULL
P.	NULL
S.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175	NULL
,	NULL
1235-1245	NULL
.	NULL

Kang	NULL
,	NULL
S.-M.	NULL
,	NULL
Beverly	NULL
,	NULL
B.	NULL
,	NULL
Tran	NULL
,	NULL
A.-C.	NULL
,	NULL
Brorson	NULL
,	NULL
K.	NULL
,	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
&	NULL
Lenardo	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Science	NULL
257	NULL
,	NULL
1134-1138	NULL
.	NULL

Serfling	NULL
,	NULL
E.	NULL
,	NULL
Barthelmas	NULL
,	NULL
R.	NULL
,	NULL
Pfeuffer	NULL
,	NULL
I.	NULL
,	NULL
Schenk	NULL
,	NULL
B.	NULL
,	NULL
Zarius	NULL
,	NULL
S.	NULL
,	NULL
Swoboda	NULL
,	NULL
R.	NULL
,	NULL
Mercurio	NULL
,	NULL
F.	NULL
&	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

8	NULL
,	NULL
465-473	NULL
.	NULL

Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
&	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8	NULL
,	NULL
421-452	NULL
.	NULL

Bohmann	NULL
,	NULL
D.	NULL
,	NULL
Bos	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Admon	NULL
,	NULL
A.	NULL
,	NULL
Nishimura	NULL
,	NULL
T.	NULL
,	NULL
Vogt	NULL
,	NULL
P.	NULL
K.	NULL
&	NULL
Tjian	NULL
,	NULL
R.	NULL
(	NULL
1987	NULL
)	NULL
Science	NULL
238	NULL
,	NULL
1386-1392	NULL
.	NULL

Reed	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Alpers	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Nowell	NULL
,	NULL
P.	NULL
C.	NULL
&	NULL
Hoover	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1986	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83	NULL
,	NULL
3982-3986	NULL
.	NULL

Risse	NULL
,	NULL
G.	NULL
,	NULL
Jooss	NULL
,	NULL
K.	NULL
,	NULL
Neuberg	NULL
,	NULL
M.	NULL
,	NULL
Bruller	NULL
,	NULL
H.	NULL
J	NULL
.	NULL

&	NULL
Muller	NULL
,	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

8	NULL
,	NULL
3825-3832	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
Imagawa	NULL
,	NULL
M.	NULL
,	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Stein	NULL
,	NULL
B.	NULL
,	NULL
Imbra	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Rahmsdorf	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Jonat	NULL
,	NULL
C.	NULL
,	NULL
Herrlich	NULL
,	NULL
P.	NULL
&	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
49	NULL
,	NULL
729-739	NULL
.	NULL

Ellenberger	NULL
,	NULL
T.	NULL
E.	NULL
,	NULL
Brandl	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Struhl	NULL
,	NULL
K.	NULL
&	NULL
Harrison	NULL
,	NULL
S.	NULL
C.	NULL
(	NULL
1992	NULL
)	NULL
Cell	NULL
71	NULL
,	NULL
1223-1237	NULL
.	NULL

Go	NULL
,	NULL
C.	NULL
&	NULL
Miller	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175	NULL
,	NULL
1327-1336	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Valge-Archer	NULL
,	NULL
V.	NULL
E.	NULL
&	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
356	NULL
,	NULL
801-804	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
Valge-Archer	NULL
,	NULL
V.	NULL
E.	NULL
,	NULL
Sinskey	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

&	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175	NULL
,	NULL
853-862	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
Valge-Archer	NULL
,	NULL
V.	NULL
E.	NULL
&	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

148	NULL
,	NULL
1240-1250	NULL
.	NULL

Barber	NULL
,	NULL
J.	NULL
R.	NULL
&	NULL
Verma	NULL
,	NULL
I	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7	NULL
,	NULL
2201-2211	NULL
.	NULL

Chiv	NULL
,	NULL
R.	NULL
,	NULL
Boyle	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Meek	NULL
,	NULL
J.	NULL
,	NULL
Smeal	NULL
,	NULL
T.	NULL
,	NULL
Hunter	NULL
,	NULL
T.	NULL
&	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
54	NULL
,	NULL
541-552	NULL
.	NULL

Ptashne	NULL
,	NULL
M.	NULL
(	NULL
1986	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
346	NULL
,	NULL
329-331	NULL
.	NULL

Ptashne	NULL
,	NULL
M.	NULL
&	NULL
Gann	NULL
,	NULL
A.	NULL
F.	NULL
(	NULL
1990	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
346	NULL
,	NULL
329-331	NULL
.	NULL

Lindsten	NULL
,	NULL
T.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Stella	NULL
,	NULL
G.	NULL
&	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
244	NULL
,	NULL
339-343	NULL
.	NULL

Hunter	NULL
,	NULL
T.	NULL
&	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
Cell	NULL
70	NULL
,	NULL
375-387	NULL
.	NULL

LeGros	NULL
,	NULL
G.	NULL
,	NULL
Ben-Sasson	NULL
,	NULL
S.	NULL
Z.	NULL
,	NULL
Seder	NULL
,	NULL
R.	NULL
,	NULL
Finkelman	NULL
,	NULL
F.	NULL
D.	NULL
&	NULL
Paul	NULL
,	NULL
W.	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172	NULL
,	NULL
921-929	NULL
.	NULL

Swain	NULL
,	NULL
S.	NULL
,	NULL
Weinberg	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
English	NULL
,	NULL
M.	NULL
&	NULL
Huston	NULL
,	NULL
G.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

145	NULL
,	NULL
3796-3806	NULL
.	NULL

Mutis	NULL
,	NULL
T.	NULL
,	NULL
Kraakman	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
Cornelisse	NULL
,	NULL
Y.	NULL
E.	NULL
,	NULL
Haanen	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

A.	NULL
G.	NULL
,	NULL
Spits	NULL
,	NULL
H.	NULL
,	NULL
DeVries	NULL
,	NULL
R.	NULL
R.P	NULL
.	NULL

&	NULL
Ottenhoff	NULL
,	NULL
T.	NULL
H.	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Infect	NULL
.	NULL

Immun	NULL
.	NULL

150	NULL
,	NULL
4641-4651	NULL
.	NULL

I	NULL

